MCAM and prostate cancer: Based on bioinformation analysis, eight putative N-glycosylation sites are present in the extracellular fragment across species.23 In clear cell renal cell carcinoma and prostate cancer, CD146 glycosylation levels were upregulated.24,25 In 2018, it was reported that CD146 glycosylation is favorably carried out by b-1,3-galactosyl-Oglycosyl-glycoprotein b-1,6-N-acetylglucosaminyltransferase-3, which was overexpressed in highly metastatic melanomas.